Biotheryx Takes Significant Step Forward in Breast Cancer Treatment with BTX-9341-101 Trial Biotheryx, Inc. has commenced the dose expansion phase of its clinical trial for BTX-9341-101, targeting HR+/HER2- breast cancer. The focus is on enhancing treatment options for patients.

Biotheryx Takes Significant Step Forward in Breast Cancer Treatment with BTX-9341-101 Trial #United_States #San_Diego #Cancer_Research #Biotheryx #BTX-9341

Biotheryx Completes Enrollment for BTX-9341 Phase 1a Trial Targeting HR+/HER2- Breast Cancer Biotheryx has successfully completed patient enrollment for its Phase 1a clinical trial of BTX-9341. This innovative treatment aims to improve outcomes for HR+/HER2- breast cancer patients.

Biotheryx Completes Enrollment for BTX-9341 Phase 1a Trial Targeting HR+/HER2- Breast Cancer #United_States #San_Diego #Breast_Cancer #Biotheryx #BTX-9341

This is a very interesting financing for those who follow #MolecularGlues #TPD #TargetedProteinDegradation round by #BioTheryX. @jaybradner @HartungIngo @MilkaKostic @elkingtonxy @ChemGenetics @CrisMayorRuiz @CraigMCrews